This content is intended for healthcare professionals only in Europe.

Please confirm that you are an EU healthcare professional.


This promotional activity has been sponsored by Jazz Pharmaceuticals. Jazz Pharmaceuticals provided financial support for this activity and has had input into the selection of the faculty and the detailed project scope. This activity is provided by Touch Medical Communications (TMC) for touchONCOLOGY.

Prescribing Information

Leukaemia View Time: 47 mins

touchSYMPOSIUM HIGHLIGHTS High-Risk* Acute Myeloid Leukaemia in 2022: What is the Go-To Strategy?

Watch leading experts present and discuss clinical and real-world evidence on the use of Vyxeos® Liposomal (Daunorubicin 44 mg / Cytarabine 100 mg) for the treatment of high-risk* acute myeloid leukaemia

*High risk AML is defined as newly diagnosed, therapy related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

  • Symposium Presentations
Curative goals: is intensive chemotherapy the antileukaemic standard of care?
Redefining survival expectations in high-risk* AML
Pursuing long-term survival in the real world

Prof. Gert Ossenkoppele
Professor of Haematology at the VU University Medical Centre, Amsterdam, The Netherlands read more

Prof. Lars Bullinger
Medical Director of the Department of Haematology, Oncology and Tumour-Immunology, Charité University Medicine, Berlin, Germany

Prof. Thomas Schroeder
Head of Stem Cell Transplantation, University Hospital Essen, Essen, Germany


Prof. Ossenkoppele: Research support/consultant/advisory boards for Agios, Amgen, Astellas, BMS, Celgene, Gilead, Helsinn, Jazz Pharmaceuticals, Johnson & Johnson, MERUS, Novartis, Pfizer, Roche.

Prof. Bullinger:
Research support/honoraria/advisory boards for Abbvie, Amgen, Astellas, Bayer, BMS, Celgene, Daiichi Sankyo, Hexal, Janssen, Jazz Pharmaceuticals, Menarini, Novartis, Pfizer, Roche, Sanofi, Seattle Genetics.

Prof. Schroeder:
Travel support/lecture fees/consultancy for Abbvie, BMS, Celgene, Jazz Pharmaceuticals, Pfizer, Takeda.

Leave Feedback
Learning Objectives & Overview

High-risk* acute myeloid leukaemia (AML) has a poor prognosis and remains a therapeutic challenge.1 In this sponsored Symposium, recorded at the 3rd European School of Haematology meeting on how to diagnose and treat acute leukaemias (ESH-AL), three leading experts present and discuss clinical and real-world evidence on the use of Vyxeos Liposomal (Daunorubicin 44mg / Cytarabine 100mg) for the treatment of high-risk* AML, and how this might change the management of the condition.2–5

*High risk AML is defined as newly diagnosed, therapy related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

Learning Objectives

After watching this activity, participants should be better able to:

  • Discuss the diagnosis, classification and prognosis of high-risk* AML
  • Review the clinical and real-world evidence on the use of Vyxeos Liposomal for the treatment of high-risk* AML
  • Discuss the impact this evidence may have on the management of high-risk*AML
Adverse Events
Adverse Events

Adverse events should be reported. Healthcare professionals are asked to report any suspected adverse events via their national reporting system. Adverse events should also be reported to Jazz Pharmaceuticals by email to

  1. Granfeldt Østgård LS, et al. Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study. J Clin Oncol. 2015;33:3641–9.
  2. Lancet JE, et al. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2021;8:e481–e491.
  3. Chiche E, et al. Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort. Blood Adv. 2021;5:176–184.
  4. Guolo F, et al. CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program. Blood Cancer J. 2020;10:96.
  5. Rautenberg C, et al. Real-world Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia. Blood Cancer J. 2021;11:164.

View and download resources from this activity to support your learning.


Feedback Close

Please provide feedback for this touchSYMPOSIUM HIGHLIGHTS on the following
(scale of 1-5 where 1=strongly disagree and 5=strongly agree):

* = Mandatory Field

Feedback Close
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72